Tech Company Financing Transactions
Adenosine Therapeutics Funding Round
On 1/25/2005, Adenosine Therapeutics raised $3.5 million in investment from Emerging Technology Partners.
Transaction Overview
Company Name
Announced On
1/25/2005
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding will allow Adenosine Therapeutics to enhance our discovery capabilities and accelerate the clinical development of our family of powerful, rapidly acting, non-steroidal anti-inflammatory drug candidates
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
P.O. Box 4632
Charlottesville, VA 22905
USA
Charlottesville, VA 22905
USA
Phone
Website
Email Address
Overview
Adenosine Therapeutics (AT), located in Charlottesville, VA, is a drug discovery and development company that was co-founded in 1999 by University of Virginia (UVa) Professor, Joel Linden and entrepreneur, Robert Capon (one of three cofounders of Virologic, NASDAQ: VLGC.)
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Joel Linden
Chief Executive Officer
Robert Capon
Chief Operating Officer
William Stilley
Controller
Robert Owen
Vice President
William Gray
Vice President
Robert Thompson
Vice President
Shannon Williams
VP - Manufacturing
Jayson Rieger
Browse more venture capital transactions:
Prev: 1/25/2005: MAP Pharmaceuticals venture capital transaction
Next: 1/26/2005: Innovative Micro Technology venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs